Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 11/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587844 | 0.84 | SLC6A4 (0.43) | CETPGPBAR1SLC6A4HTR2CHTR2B | |
| SCHEMBL4506280 | 0.79 | CETP (0.47) | CETPMEN1KMT2A | |
| SCHEMBL4494930 | 0.76 | CETP (0.41) | CETPPTGER1 | |
| SCHEMBL4490427 | 0.76 | CETP (0.39) | CETPGPBAR1 | |
| SCHEMBL132751 | 0.76 | ALDH1A1 (0.40) | CETPGPBAR1PTGER1MEN1KMT2A | |
| SCHEMBL130203 | 0.75 | CETP (0.45) | CETPSLC6A4HTR2CHTR2BPTGER1 | |
| SCHEMBL1588216 | 0.73 | HTR2C (0.39) | CETPSLC6A4HTR2CHTR2BPTGER1 | |
| SCHEMBL1587559 | 0.72 | CETP (0.46) | CETPSLC6A4PTGER1 | |
| SCHEMBL1588411 | 0.72 | CETP (0.53) | CETP | |
| SCHEMBL4504221 | 0.71 | CETP (0.40) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885GPBAR1 270/4885SLC6A4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.